Proceedings
Immunoinformatics Prediction of T-cell and B-cell Epitopes from Major Protein Allergen Der p 1 Presented by HLA Alleles Predominant in Indonesian Population
In the past decades, the allergic disease prevalence has been increasing worldwide. It is estimated that 5-30% of populations in all America, Southeast Asia (such as Indonesia, Malaysia, Thailand, Singapore, etc), Europe, and Australia have sensitivity and/or skin reactivity towards dust mites. House dust mites (HDM) are able to cause severe allergic reactions as well as represent the biggest source of indoor allergens. Der p 1 is an allergen from Dermatophagoides pteronyssinus, the most common HDM species, which is also known as the major allergen from this species. Thus, Der p 1 allergen is a good candidate as a promising target to develop an effective vaccine allergy against HDM. CTLs (Cytotoxic T lymphocytes) epitopes, HTLs (Helper T lymphocytes) epitopes, B cell epitopes, adjuvant, and linkers, are the key multi-epitope, peptide-based, vaccine allergy components. The prediction of promiscuous HTL and CTL epitopes were done through “NetMHCIIpan 4.0 server” and “NetCTLpan-1.1”, respectively. Promiscuous epitopes were filtered through the IFNepitope server and IEDB immunogenicity tool. IFNγ is a signature cytokine produced by Th1 cells that is important for immune tolerance induction. Therefore, the promiscuous epitope with a high IFNγ inducing ability and immunogenicity were chosen as the candidate for vaccine construct. B cell epitopes were generated from three different tools. Two overlapping sequences recognized from these three tools were being included in the vaccine construct. Selected epitopes for vaccine construction were determined by a specific criterias such as the selected epitope combination should be able to cover a high amount of HLA alleles in Indonesia population, which resulted in the selection of five CTL epitopes, two B cell epitopes, and one HTL epitopes. There are eight epitopes, four linkers (KK, EAAAK, GPGPG, AAY linkers) and one adjuvant (β-defensin) were selected in the vaccine construct to increase epitope presentation. The vaccine construct showed a good coverage for the Indonesian population which was more than 90%.
No other version available